loading
Schlusskurs vom Vortag:
$14.47
Offen:
$14.68
24-Stunden-Volumen:
1.32M
Relative Volume:
0.49
Marktkapitalisierung:
$46.71B
Einnahmen:
$29.63B
Nettoeinkommen (Verlust:
$260.53M
KGV:
187.63
EPS:
0.0788
Netto-Cashflow:
$5.51B
1W Leistung:
+2.74%
1M Leistung:
+5.08%
6M Leistung:
-0.77%
1J Leistung:
+12.78%
1-Tages-Spanne:
Value
$14.66
$14.79
1-Wochen-Bereich:
Value
$14.20
$14.79
52-Wochen-Spanne:
Value
$12.80
$15.69

Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile

Name
Firmenname
Takeda Pharmaceutical Co Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
47,455
Name
Twitter
@takedapharma
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
TAK's Discussions on Twitter

Vergleichen Sie TAK mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.79 45.71B 29.63B 260.53M 5.51B 0.0788
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
124.30 53.87B 9.40B 2.65B 2.24B 5.935
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.905 43.73B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
29.98 34.49B 16.88B 666.71M 251.19M 0.6132
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
509.07 22.00B 3.08B 1.24B 1.07B 25.61

Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-02 Hochstufung Morgan Stanley Equal-Weight → Overweight
2023-03-16 Hochstufung BofA Securities Neutral → Buy
2022-07-19 Hochstufung Cowen Market Perform → Outperform
2021-10-07 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-04-19 Herabstufung JP Morgan Overweight → Neutral
2019-11-01 Eingeleitet Cowen Market Perform
2019-08-15 Herabstufung Daiwa Securities Outperform → Neutral
Alle ansehen

Takeda Pharmaceutical Co Adr Aktie (TAK) Neueste Nachrichten

pulisher
Dec 15, 2025

Takeda Pharmaceutical Co Ltd (TAK) Bonds - GuruFocus

Dec 15, 2025
pulisher
Dec 10, 2025

Celiac Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.

Dec 10, 2025
pulisher
Dec 06, 2025

Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - GlobeNewswire Inc.

Dec 06, 2025
pulisher
Dec 05, 2025

Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz

Dec 05, 2025
pulisher
Dec 04, 2025

INNOVENT BIO Completes Introduction of Takeda, Raising ~HKD780M Net - AASTOCKS.com

Dec 04, 2025
pulisher
Dec 02, 2025

TAK vs. DSNKY: Which Stock Is the Better Value Option? - MSN

Dec 02, 2025
pulisher
Nov 18, 2025

Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Nov 18, 2025
pulisher
Nov 04, 2025

Coca-Cola Upgraded, Boeing Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Nov 04, 2025
pulisher
Nov 02, 2025

ADR movements on the 11th: In yen terms, Kirin HD, Takeda Pharmaceutical, and Mitsui Metals showed gains. - 富途牛牛

Nov 02, 2025
pulisher
Oct 30, 2025

Takeda Pharma ADR earnings beat by $278.84, revenue fell short of estimates - Investing.com Nigeria

Oct 30, 2025
pulisher
Oct 24, 2025

CMBI Adds INNOVENT BIO (01801.HK) TP to $110.62 on Strategic Partnership with Takeda Pharmaceutical - AASTOCKS.com

Oct 24, 2025
pulisher
Oct 22, 2025

BofAS Elevates INNOVENT BIO (01801.HK) TP to $113 as Co-op with Takeda Pharmaceutical Marks Major Step Towards Becoming Multinational Pharma Firm - AASTOCKS.com

Oct 22, 2025
pulisher
Oct 22, 2025

CLSA Lifts INNOVENT BIO's TP to HKD120.1; Takeda Pharma Co-op Positive for Product Development - AASTOCKS.com

Oct 22, 2025
pulisher
Oct 21, 2025

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors - Placera.se

Oct 21, 2025
pulisher
Oct 21, 2025

INNOVENT BIO Opens Up 10% on Shr Issuance to Takeda Pharma at ~30% Premium w/ Licensing Deal Worth USD11.4B - AASTOCKS.com

Oct 21, 2025
pulisher
Oct 21, 2025

INNOVENT BIO Issues Shrs at ~30% Premium to Takeda Pharma w/ Licensing Deal Involving USD11.4B - AASTOCKS.com

Oct 21, 2025
pulisher
Oct 20, 2025

Bank of America Upgraded, Allstate Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Oct 20, 2025
pulisher
Oct 13, 2025

Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Oct 13, 2025
pulisher
Oct 08, 2025

Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo

Oct 08, 2025
pulisher
Sep 26, 2025

Pharma stocks in Asia fall as Trump announces 100% tariffs - Investing.com

Sep 26, 2025
pulisher
Sep 17, 2025

5 Best High-Yield Dividend Stocks to Buy Now - The Motley Fool

Sep 17, 2025
pulisher
Sep 08, 2025

Takeda’s narcolepsy drug shows positive results in phase 3 trials - Investing.com

Sep 08, 2025
pulisher
Sep 06, 2025

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease - Placera.se

Sep 06, 2025
pulisher
Aug 25, 2025

Japan's Takeda weighs India for global trials to speed up drug launches - MSN

Aug 25, 2025
pulisher
Aug 22, 2025

Takeda Pharmaceutical ADR Earns RS Rating Upgrade - MSN

Aug 22, 2025
pulisher
Aug 22, 2025

IBD Rating Upgrades: Warrior Met Coal Shows Improved Technical Strength - inkl

Aug 22, 2025
pulisher
Aug 21, 2025

IBD Rating Upgrades: Takeda Pharmaceutical ADR Shows Improved Technical Strength - MSN

Aug 21, 2025
pulisher
Aug 20, 2025

IBD Rating Upgrades: Genmab ADR Shows Improved Relative Price Strength - inkl

Aug 20, 2025
pulisher
Aug 18, 2025

Waltham biotech’s latest pharma deal valued at $2B - The Business Journals

Aug 18, 2025

Finanzdaten der Takeda Pharmaceutical Co Adr-Aktie (TAK)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_specialty_generic HLN
$9.90
price up icon 0.81%
drug_manufacturers_specialty_generic ZTS
$124.36
price up icon 1.73%
$29.97
price down icon 0.36%
$509.41
price down icon 0.37%
$141.41
price down icon 0.12%
Kapitalisierung:     |  Volumen (24h):